vs
Side-by-side financial comparison of Dexcom (DXCM) and Eastman Chemical Company (EMN). Click either name above to swap in a different company.
Eastman Chemical Company is the larger business by last-quarter revenue ($2.0B vs $1.3B, roughly 1.6× Dexcom). Dexcom runs the higher net margin — 21.2% vs 5.3%, a 15.9% gap on every dollar of revenue. On growth, Dexcom posted the faster year-over-year revenue change (21.6% vs -13.8%). Over the past eight quarters, Dexcom's revenue compounded faster (12.0% CAGR vs -8.6%).
Dexcom, Inc. is an American multinational healthcare company that develops, manufactures, produces and distributes a line of continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with global headquarters and R&D center in San Diego, California, U.S.A. and manufacturing facilities in Mesa, Arizona, U.S.A.; Batu Kawan, Malaysia and Athenry, County Galway, Ireland.
Eastman Chemical Company is an American chemical products manufacturer based in Kingsport, Tennessee. Founded in 1920, it was formerly a subsidiary of Kodak until 1994. The company is an independent global specialty materials company that produces a broad range of advanced materials, chemicals and fibers for everyday purposes. It operates 36 manufacturing sites worldwide and employs approximately 14,000 people. In 2023, Eastman had sales revenue of approximately $9.21 billion.
DXCM vs EMN — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.3B | $2.0B |
| Net Profit | $267.3M | $105.0M |
| Gross Margin | 62.9% | 17.1% |
| Operating Margin | 25.6% | — |
| Net Margin | 21.2% | 5.3% |
| Revenue YoY | 21.6% | -13.8% |
| Net Profit YoY | 153.6% | -42.3% |
| EPS (diluted) | $0.67 | $0.93 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $1.3B | $2.0B | ||
| Q4 25 | $1.3B | $2.0B | ||
| Q3 25 | $1.2B | $2.2B | ||
| Q2 25 | $1.2B | $2.3B | ||
| Q1 25 | $1.0B | $2.3B | ||
| Q4 24 | $1.1B | $2.2B | ||
| Q3 24 | $994.2M | $2.5B | ||
| Q2 24 | $1.0B | $2.4B |
| Q1 26 | $267.3M | $105.0M | ||
| Q4 25 | $267.3M | $105.0M | ||
| Q3 25 | $283.8M | $47.0M | ||
| Q2 25 | $179.8M | $140.0M | ||
| Q1 25 | $105.4M | $182.0M | ||
| Q4 24 | $151.7M | $330.0M | ||
| Q3 24 | $134.6M | $180.0M | ||
| Q2 24 | $143.5M | $230.0M |
| Q1 26 | 62.9% | 17.1% | ||
| Q4 25 | 62.9% | 17.1% | ||
| Q3 25 | 60.5% | 19.7% | ||
| Q2 25 | 59.5% | 22.1% | ||
| Q1 25 | 56.9% | 24.8% | ||
| Q4 24 | 58.9% | 24.7% | ||
| Q3 24 | 59.7% | 24.6% | ||
| Q2 24 | 62.4% | 25.3% |
| Q1 26 | 25.6% | — | ||
| Q4 25 | 25.6% | 0.6% | ||
| Q3 25 | 20.1% | 6.1% | ||
| Q2 25 | 18.4% | 7.4% | ||
| Q1 25 | 12.9% | 11.0% | ||
| Q4 24 | 17.0% | 13.2% | ||
| Q3 24 | 15.3% | 11.4% | ||
| Q2 24 | 15.7% | 12.1% |
| Q1 26 | 21.2% | 5.3% | ||
| Q4 25 | 21.2% | 5.3% | ||
| Q3 25 | 23.5% | 2.1% | ||
| Q2 25 | 15.5% | 6.1% | ||
| Q1 25 | 10.2% | 7.9% | ||
| Q4 24 | 13.6% | 14.7% | ||
| Q3 24 | 13.5% | 7.3% | ||
| Q2 24 | 14.3% | 9.7% |
| Q1 26 | $0.67 | $0.93 | ||
| Q4 25 | $0.67 | $0.93 | ||
| Q3 25 | $0.70 | $0.40 | ||
| Q2 25 | $0.45 | $1.20 | ||
| Q1 25 | $0.27 | $1.57 | ||
| Q4 24 | $0.37 | $2.81 | ||
| Q3 24 | $0.34 | $1.53 | ||
| Q2 24 | $0.35 | $1.94 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $917.7M | $566.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.7B | $6.0B |
| Total Assets | $6.3B | $14.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $917.7M | $566.0M | ||
| Q4 25 | $917.7M | $566.0M | ||
| Q3 25 | $1.8B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $904.9M | — | ||
| Q4 24 | $606.1M | $837.0M | ||
| Q3 24 | $621.2M | — | ||
| Q2 24 | $939.2M | — |
| Q1 26 | $2.7B | $6.0B | ||
| Q4 25 | $2.7B | $6.0B | ||
| Q3 25 | $2.7B | $5.8B | ||
| Q2 25 | $2.6B | $5.8B | ||
| Q1 25 | $2.3B | $5.9B | ||
| Q4 24 | $2.1B | $5.8B | ||
| Q3 24 | $2.0B | $5.7B | ||
| Q2 24 | $2.4B | $5.6B |
| Q1 26 | $6.3B | $14.9B | ||
| Q4 25 | $6.3B | $14.9B | ||
| Q3 25 | $7.5B | $15.0B | ||
| Q2 25 | $7.3B | $15.2B | ||
| Q1 25 | $6.8B | $15.0B | ||
| Q4 24 | $6.5B | $15.2B | ||
| Q3 24 | $6.4B | $15.1B | ||
| Q2 24 | $6.8B | $14.9B |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
